津力达颗粒联合利拉鲁肽治疗2型糖尿病的临床研究

目的探讨津力达颗粒联合利拉鲁肽注射液治疗2型糖尿病的临床疗效。方法选取2014年7月—2016年7月漯河市中心医院收治的2型糖尿病患者90例为研究对象,所有患者采用计算机随机分为对照组和治疗组,每组各45例。对照组皮下注射利拉鲁肽注射液,起始剂量为0.6 mg/次,根据空腹血糖水平调节用量至1.2 mg/次,至少一周后将剂量增加为1.8mg/次,1次/d。治疗组在对照组基础上口服津力达颗粒,1袋/次,3次/d。两组患者均连续治疗12周。观察两组的临床疗效,比较两组的血糖相关指标、氧化应激指标和血清学指标。结果治疗后,对照组和治疗组的总有效率分别为82.22%、95.56%,两组比较差异具有统计学意义(P0.05)。治疗后,两组空腹血糖(FBG)、餐后2 h血糖(2 h PG)、糖化血红蛋白(Hb A1c)、空腹胰岛素(FINS)、丙二醛(MDA)水平显著降低,超氧化物歧化酶(SOD)和谷胱甘肽过氧化物酶(GSH-Px)水平显著升高,同组治疗前后比较差异具有统计学意义(P0.05);且治疗组这些观察指标的改善程度明显优于对照组,两组比较差异具有统计学意义(P0.05)。治疗后,两组颗粒蛋白前体(PGRN)、富含半胱氨酸的酸性分泌蛋白(SPARC)、单核细胞趋化蛋白-1(MCP-1)和血管细胞间黏附分子-1(VCAM-1)水平显著降低,分泌型卷曲相关蛋白-5(SFRP5)水平显著增加,同组治疗前后比较差异具有统计学意义(P0.05);且治疗组这些观察指标的改善程度明显优于对照组,两组比较差异具有统计学意义(P0.05)。结论津力达颗粒联合利拉鲁肽注射液治疗2型糖尿病具有较好的临床疗效,可改善氧化应激状态,降低机体炎症反应,具有一定的临床推广应用价值。

Clinical study on Jinlida Granules combined with liraglutide in treatment of type 2 diabetes mellitus

Objective To investigate the clinical effect of Jinlida Granules combined with Liraglutide Injection in treatment of type 2 diabetes mellitus. Methods Patients (90 cases) with type 2 diabetes mellitus in Luohe Central Hospital from January 2013 to February 2015 were randomly divided into control and treatment groups, and each group had 45 cases. Patients in the control group were sc administered with Liraglutide Injection, starting dose 0.6 mg/time, after a week, dose adjustment to 1.8 mg/time, once daily. Patients in the treatment group were po administered with Jinlida Granules on the basis of the control group, 1 bag/time, three times daily. Patients in two groups were treated for 12 weeks. After treatment, the clinical efficacies were evaluated, and blood glucose related indexes, oxidative stress indexes, and serological indexes in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 82.22% and 95.56%, respectively, and there was difference between two groups (P < 0.05). After treatment, the levels of FBG, 2 hPG, HbA1c, FINS SOD, and GSH-Px in two groups were significantly decreased, but the levels of MDA in two groups were significantly decreased, and the difference was statistically significant in the same group (P < 0.05). And the observational indexes in the treatment group were significantly better than those in the control group, with significant difference between two groups (P < 0.05). After treatment, the levels of PGRN, SPARC, MCP-1, and VCAM-1 in two groups were significantly decreased, but the levels of SFRP5 in two groups were significantly increased, and the difference was statistically significant in the same group (P < 0.05). And the observational indexes in the treatment group were significantly better than those in the control group, with significant difference between two groups (P < 0.05). Conclusion Jinlida Granules combined with Liraglutide Injection has clinical curative effect in treatment of type 2 diabetes mellitus, can improve the state of oxidative stress, reduce the inflammatory response, which has a certain clinical application value.